Quantcast

Latest Zonisamide Stories

2014-06-30 12:26:21

LONDON, June 30, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Seizures - Pipeline Review, H1 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/seizures_pipeline_review_h1_2013.html Seizures - Pipeline Review, H1 2014 SummaryGlobal Markets Direct's, 'Seizures - Pipeline Review, H1 2014', provides an overview of the Seizures's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Seizures,...

2011-09-01 04:20:02

Looks to Expand Global Epilepsy Product Portfolio Tokyo, Sept 1, 2011 - (JCN Newswire) - Eisai Co., Ltd. announced today that 35 abstracts highlighting the latest results from studies with its pipeline and portfolio products (perampanel: 5 abstracts, Zonegran(R): 5 abstracts, Zebinix(R): 25 abstracts) were presented at the 29th International Epilepsy Congress which took place in Italy (Rome) between August 28 and September 1, 2011. This research demonstrates...

2011-01-25 01:22:00

HATFIELD, England, Jan. 25, 2011 /PRNewswire/ -- Eisai announced today that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of partial seizures in patients with...

2011-01-13 07:21:00

HATFIELD, England, January 13, 2011 /PRNewswire-FirstCall/ -- - Epilepsy Treatment Zonegran(R) First Commercially Available Product Eisai Europe Limited, a subsidiary of Eisai Co., Ltd (Headquarters: Tokyo; President and CEO: Haruo Naito) announces the establishment of its sales and marketing operation in its wholly owned subsidiary in the Netherlands based in Amsterdam. The first Eisai product on the Dutch market is the epilepsy treatment Zonegran (zonisamide). Commenting...

2010-06-29 06:30:00

ATLANTA, June 29 /PRNewswire/ -- New long term data showed that Vimpat® (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs)...

2009-09-30 07:00:00

SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo. The Company plans to meet...

2009-02-19 09:02:00

LONDON, February 19 /PRNewswire-FirstCall/ -- - Eisai Set to Become an Emerging Leader in the Treatment of Epilepsy Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), and Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, CEO Dr Luis Portela) today announced the signing of a licence and co-promotion agreement in which Eisai receives a sole license to market, promote and...

2008-10-06 15:00:07

PHOENIX, Oct. 6 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced that the company reviewed in an oral presentation at The Obesity Society Annual Scientific Meeting that the investigational drug, Empatic(TM) (zonisamide SR/bupropion SR), demonstrated up to 15% reduction in body weight of healthy obese people who completed 48-weeks of treatment in the...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related